Oncolytics Biotech Q1 EPS $(0.07) Beats $(0.08) Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech (NASDAQ:ONCY) reported Q1 losses of $(0.07) per share, surpassing the analyst consensus estimate of $(0.08) by 12.5%. The performance is consistent with the same period last year.
May 09, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncolytics Biotech reported better-than-expected Q1 earnings, with a loss of $(0.07) per share against estimates of $(0.08).
Beating earnings estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The consistency with last year's performance also indicates stability.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100